和厚朴酚的抗肿瘤实验治疗及其分子作用靶点的研究进展  

Research progress in anticancer effects and molecular targets of honokiol in experimental therapy

作　　者：陈淑珍[1] 

机构地区：[1]中国医学科学院北京协和医学院医药生物技术研究所,北京100050

出　　处：《药学学报》2016年第2期202-207,共6页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81373437)

摘　　要：和厚朴酚(honokiol,HNK)是中药厚朴的主要活性成分之一,具有广泛的生物学作用,如中度抗肿瘤活性。和厚朴酚能够在体内外抑制肺癌、胃肠道肿瘤、头颈部鳞癌、乳腺癌、前列腺癌和卵巢癌等肿瘤的生长,作用靶点广泛,能调节凋亡相关信号通路,抑制生长因子介导的信号通路,阻断NF-κB信号通路,减少雄激素受体的表达,抑制m TOR和STAT3信号通路等。HNK能增加传统抗肿瘤药物或靶向抗肿瘤药物的抑瘤作用,逆转肿瘤细胞对顺铂、多柔比星和紫杉醇等的耐药性。可见,和厚朴酚与抗肿瘤药物联用具有增效和逆转耐药性的作用,可作为生化调节剂应用于临床。Honokiol（HNK）, one of major biological active constituents of Mangnolia officinalis, exerts a wide range of biological functions, such as moderate anticancer effects. It inhibits the growth of lung cancer, gastrointestinal cancer, head and neck squamous cell carcinoma, breast cancer, prostate cancer, ovarian cancer, in vitro and in vivo through multiple potential molecular targets. It modulates apoptosis-associated signaling pathway, inhibits growth factor receptor-mediated signal transduction pathway, blocks nuclear factor-κB signaling pathway, decreases the expression level of androgen receptors, subsides m TOR and STAT3 signaling pathway, and so on. HNK enhances the inhibitory effects of traditional anticancer drugs or targeted antitumor drugs in vitro and in vivo. It reverses multidrug resistances of cancer cells to cisplatin, doxorubicin and paclitaxol. Therefore, HNK plays a role in the augmentation of antitumor effects of cancer drugs and the reversal of multidrug resistance of tumor cells. HNK is a promising biochemical modulator of anti-cancer medicines in the cancer therapy.

关 键 词：和厚朴酚 抗肿瘤药物 实验治疗 分子靶点 耐药性 

分 类 号：R979.1[医药卫生—药品]